M.M. Fael - Post-graduate Student, Department of Tumors of the Skin, Soft Tissues, Breast Beds Thoracic Surgery, Russian Scientific Center of Roentgen Radiology MH RF, Moscow. E-mail: dutsun@list.ru O.P. Bliznyukov - Dr. Sc. (Med), Head of the Department of Pathology, Russian Scientific Center of Roentgen Radiology (RSCRR) MH RF N.V. Melnikova - Ph. D. (Med), Leading Researcher Scientist, Laboratory of Immunology, Stem Cell Technologies in On-cology, Russian Scientific Center of Roentgen Radiology (RSCRR) MH RF

For infiltrating breast cancers with basal cell differentiation characterized by high frequency of hematogenous metastases that are detected in 43.5% of patients, which is significantly higher than in patients with infiltrative breast cancer with luminal differentiation of cells and triple negative phenotype. Тhe Most common sites of metastases is the liver (26%), bones (26%), lung (21%). Half of the patients with infiltrative breast cancer with basal cell differentiation have clinical stage of the disease II A-В and III А-B. For these cancers are not detected early (stage Тis) and late (IIIC and IV) stage disease is characterized by the ingrowth of the tumor in the breast skin, chest muscle and metastases in more than 10 lymph nodes. Overall 5 year survival rate of patients with infiltrative breast cancer with basal cell differentiation is 73,7%. This is 20% less than in patients with infiltrative carcinoma with luminal (A+B) phenotype, and 6% less than in patients with infil-trative cancer with triple negative phenotype. Factors that determine adverse clinical outcome, is the high incidence of hematogenous metastases and resistance of the tumor to hormonal and targeted therapy.

 

1. Kaprin A.D., Starinskijj V.V., Petrova G.V.Zlokachestvennye novoobrazovanija v Rossii v 2012 godu (zabolevaemost i smertnost) M. 2014. URL: www.oncology.ru/service/statistics/morbidity/2012.pdf
2. Kuligina E.SH.EHpidemiologicheskie i molekuljarnye aspekty raka molochnojj zhelezy // Prakticheskaja onkologija. 2010. № 11. S. 203-216.
3. Semiglazov V.F., Semiglazov V.V., Manikhas A.G.Rak molochnojj zhelezy. KHimioterapija i targetnaja terapija. M.: MEDpressinform. 2012. 360 s.
4. Semiglazov V.F., Manikhas A.G., Semiglazova T.JU., Bessonov A.A.,Semiglazov V.V. Neoadjuvantnaja sistemnaja terapija raka molochnojj zhelezy: Rukovodstvo dlja vrachejj. SPb.: AGRAF. 2012. 112 s.
5. Stenina M.B., Frolova M., Skrypnikova M., Tjuljandin S.A. Bazalnopodobnyjj (trojjnojj negativnyjj) rak molochnojj zhelezy: molekuljarnye osobennosti, techenie i vozmozhnye terapevticheskie podkhody // Vrach. 2010. № 3. S. 24-28.
6. Allred D.C., Harvey J.M., Berado M., Clark J.M. Prognostic and predictive factors in breast cancer by immunohystochemical analysis // Mod. pathol. 1998. V. 11. R. 155-168.
7. Bertucci F., Finetti P., Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype // Curr. Mol. Med. 2012. V. 12. № 1. P. 96-110.
8. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K. et al. Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study // JAMA. 2006. V. 295. № 21.  R. 2492-2502.
9. Cheang M. C., Voduc D., Bajdik C. et al.Basal-like breast cancer defined by five biomarkers has superior prognostic value to triple - negative phenotype // Clin. Cancer Res. 2008. V.14.  P.1368-1376.
10. Dawood S, Broglio K, Esteva FJ, et al. Survival among women with triple receptor-negative breast cancer and brain metastases //Ann Oncol.2009. V.20. № 4. R. 621-627.
11. Dairkee S.H., Puett L., Hackett A.J. Expression of basal and luminal epithelium-specific keratins in normal, benign, and malignant breast tissue // J. Natl. Cancer Inst. 1988. V. 80. №9. R.691-695.
12. Fulford L.G., Reis-Filho J.S., Ryder K., et al.Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival // Breast Cancer Res. 2007. V. 9. № 1. P. 4.
13. Moll R., Franke W.W., Schiller D.L., Geiger B., Krepler R.The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells // Cell. 1982. V. 31. № 1. R.11-24.
14. Morris G.J., Naidu S., Topham A.K., et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute-s Surveillance, Epidemiology, and End Results database // Cancer.2007. V.110. R.876-884.
15. Nielsen T.O.,Hsu F.D.,Jensen K.,Cheang M., et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma // Clin Cancer Res.2004. V. 15. № 10. R.5367-5374.
16. Rakha E., Elsheikh S., Aleskandarany M. et al. riple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes // Clin Cancer Res. 2009. V. 15. № 7. R. 2302-2310.
17. Tavassoli F. A., Devilee P.Rathology and genetics of tumors of the breast and female genital organs // IARC. Lyon. 2003. P.432.
18. Wolff A. C., Hammond M. E. H., Schwartz J. N. et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer // Archives of Pathology & Laboratory Medicine. 2007. V. 131. № 1. P. 18-43.